4D Molecular Therapeutics, Inc. (FDMT)

Market Cap	688.66M
Revenue (ttm)	1.97M
Net Income (ttm)	-105.20M
Shares Out	32.39M
EPS (ttm)	-3.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218,052
Open	20.23
Previous Close	20.23
Day's Range	19.87 - 21.30
52-Week Range	5.32 - 26.49
Beta	2.75
Analysts	Buy
Price Target	36.72 (+72.72%)
Earnings Date	Mar 27, 2023

About FDMT

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which i...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. John F. Milligan Ph.D.
• Employees: 140
• Stock Exchange: NASDAQ
• Ticker Symbol: FDMT

Financial Performance

In 2021, FDMT's revenue was $18.04 million, an increase of 32.52% compared to the previous year's $13.61 million. Losses were -$71.32 million, 25.8% more than in 2020.

Analyst Forecast

According to 12 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $36.72, which is an increase of 72.72% from the latest price.

Price Target

$36.72

(72.72% upside)

Analyst Consensus: Buy